Skip to main content
Supplement ScienceSupplementScience

Benefits of Zeaxanthin

Evidence:Strong
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • Foveal protection — zeaxanthin is the dominant carotenoid in the foveal center, where it absorbs blue light at 400-500 nm wavelengths, protecting cone photoreceptors
  • AMD risk reduction — the AREDS2 trial demonstrated that 2 mg zeaxanthin combined with 10 mg lutein effectively replaced beta-carotene for advanced AMD prevention
  • Antioxidant activity — zeaxanthin quenches singlet oxygen more efficiently than many other carotenoids, protecting retinal lipids from peroxidation (Li et al., 2010)
  • Visual performance — supplementation improves glare recovery time and photostress recovery, enhancing visual comfort in bright conditions

What the Research Says

Zeaxanthin is a carotenoid that plays a significant role in eye health, particularly in reducing the risk of age-related macular degeneration (AMD) and cataracts. The AREDS2 trial (Age-Related Eye Disease Study 2 Research Group, 2013) demonstrated that lutein combined with zeaxanthin is a safer and equally effective alternative to beta-carotene for AMD prevention. This combination was found to be particularly beneficial due to its ability to increase macular pigment optical density (MPOD), which is critical for central visual acuity.

Epidemiological studies consistently show that higher dietary intake of zeaxanthin is associated with a reduced risk of AMD. A systematic review and meta-analysis by Ma et al. (2012) found that higher lutein and zeaxanthin intake was linked to a 30-40% lower risk of late AMD, with a relative risk reduction of 0.74 (CI 0.57-0.97). Additionally, a meta-analysis by Ma et al. (2016) involving 20 randomized controlled trials (RCTs) with 938 AMD patients and 826 healthy subjects found that supplementation with lutein, zeaxanthin, and meso-zeaxanthin significantly increased MPOD in both groups.

Zeaxanthin also plays a role in reducing the risk of cataracts. A meta-analysis by Liu et al. (2014) of eight studies found that higher blood levels of lutein and zeaxanthin were associated with a reduced risk of nuclear cataracts. Furthermore, Ma et al. (2014) conducted a dose-response meta-analysis of six prospective cohort studies involving 41,999 participants, which showed that higher dietary intake of lutein and zeaxanthin was associated with a reduced risk of nuclear cataract in a dose-dependent manner.

In summary, zeaxanthin supplementation is supported by robust evidence from clinical trials and meta-analyses, highlighting its role in reducing the risk of AMD and cataracts while improving macular pigment density.

Related Conditions

Eye Health
Full Zeaxanthin Guide

References

  1. RCTAge-Related Eye Disease Study 2 Research Group (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. DOI PubMed
  2. ObservationalBone RA, Landrum JT, Mayne ST, et al. (2001). Macular pigment in donor eyes with and without AMD: a case-control study. Investigative Ophthalmology & Visual Science. PubMed
  3. Meta-analysisChoo YM, Yip KX, Fiander M, Ahmad Kamar A, et al. (2025). Lutein and zeaxanthin for reducing morbidity and mortality in preterm infants.. The Cochrane database of systematic reviews. DOI PubMed
  4. Meta-analysisWilson LM, Tharmarajah S, Jia Y, Semba RD, et al. (2021). The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis.. Advances in nutrition (Bethesda, Md.). DOI PubMed
  5. Meta-analysisMa L, Liu R, Du JH, Liu T, et al. (2016). Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density.. Nutrients. DOI PubMed
  6. Meta-analysisLiu XH, Yu RB, Liu R, Hao ZX, et al. (2014). Association between lutein and zeaxanthin status and the risk of cataract: a meta-analysis.. Nutrients. DOI PubMed
  7. Meta-analysisMa L, Hao ZX, Liu RR, Yu RB, et al. (2014). A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract.. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. DOI PubMed
Show 5 more references
  1. Meta-analysisLiu R, Wang T, Zhang B, Qin L, et al. (2014). Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration.. Investigative ophthalmology & visual science. DOI PubMed
  2. Meta-analysisMa L, Dou HL, Wu YQ, Huang YM, et al. (2012). Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis.. The British journal of nutrition. DOI PubMed
  3. ObservationalKeenan TDL, Agrón E, Keane PA, Domalpally A, et al. (2025). Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.. Ophthalmology. DOI PubMed
  4. RCTLopresti AL, Smith SJ (2025). The effects of lutein/ zeaxanthin (Lute-gen®) on eye health, eye strain, sleep quality, and attention in high electronic screen users: a randomized, double-blind, placebo-controlled study.. Frontiers in nutrition. DOI PubMed
  5. ReviewMartinez-Perez C, Oliveira AP (2025). Nutritional Supplementation for Myopia Prevention and Control: A Systematic Review of Randomized Controlled Trials.. Nutrients. DOI PubMed